Jin Wook (Miles) Suk - Nov 13, 2024 Form 4/A - Amendment Insider Report for Abpro Holdings, Inc. (ABP)

Role
Co-CEO & Chairman, Director
Signature
/s/ Nelson Mullins Riley & Scarborough LLP, Attorney-in-Fact
Stock symbol
ABP
Transactions as of
Nov 13, 2024
Transactions value $
$0
Form type
4/A - Amendment
Date filed
11/25/2024, 09:58 PM
Date Of Original Report
Nov 15, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABP Stock option (right to buy) Award $0 +614K $0.00 614K Nov 13, 2024 Common Stock, par value $0.0001 per share 614K $1.63 By Biocelsus International Co. Ltd. F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On November 15, 2024, the reporting person filed a Form 4 which inadvertently omitted the transaction disclosed hereby.
F2 Reflects the issuance by Abpro Holdings, Inc. (f/k/a Atlantic Coastal Acquisition Corp. II) (the "Issuer") on November 13, 2024, of rollover stock option awards in connection with the business combination between the Issuer and Abpro Corporation, a Delaware corporation ("Abpro"), pursuant to a Business Combination Agreement, dated as of December 11, 2023 (as amended by Amendment No. 1 to Business Combination Agreement, dated September 4, 2024, the "Business Combination Agreement"), by and among the Issuer, Abpro Merger Sub Corp, a Delaware corporation, and Abpro.
F3 This stock option award is 100% vested.
F4 Biocelsus International Co. Ltd. is controlled by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.